SOTERIA Collaborates with Tempus to Advance Precision Oncology for U.S. Military and Veterans Battling Cancer

SOTERIA Precision Medicine Foundation announced a collaboration with Tempus (NASDAQ: TEM) to provide cancer treatment insights for U.S. service members and veterans.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Positive)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

SOTERIA Precision Medicine Foundation announced a collaboration with Tempus (NASDAQ: TEM) to provide cancer treatment insights for U.S. service members and veterans.

The collaboration supports SOTERIA's Cancer Hunt initiative, combining patient navigation with Tempus' genomic profiling and AI-enabled diagnostic platform to help identify targeted therapies and clinical trial opportunities. The organizations plan to continue streamlining molecular profiling and data integration across SOTERIA's patient cohort to support precision oncology research and care pathways.

Key Terms

genomic profiling, germline sequencing, somatic sequencing

3 terms

genomic profiling medical

"Tempus' comprehensive genomic profiling and AI-enabled diagnostic platform"

Genomic profiling is the process of reading a person’s or tumor’s genetic blueprint to identify mutations or patterns that affect disease behavior and treatment response. For investors, it matters because these profiles guide development and use of targeted therapies and diagnostics, shaping clinical trial success, market demand, regulatory approval, and potential revenue—much like a detailed map that helps developers choose the most promising routes and avoid dead ends.

germline sequencing medical

"facilitating CLIA-validated germline and somatic sequencing"

Germline sequencing is the laboratory reading of an individual’s inherited DNA sequence as found in reproductive cells and every normal cell of the body, used to identify genetic variants that are present from birth and can be passed to offspring. It typically analyzes blood or saliva samples to detect single-letter changes, insertions/deletions, or larger inherited alterations across selected genes or the whole genome; unlike somatic (tumor) sequencing, germline results represent constitutional, heritable variants rather than changes acquired only in diseased tissue.

somatic sequencing medical

"facilitating CLIA-validated germline and somatic sequencing"

Sequencing of DNA or RNA from a person’s somatic (non‑reproductive) cells to identify acquired genetic changes that are not inherited. It typically analyzes tissue or circulating tumor DNA using next‑generation sequencing to detect mutations, copy‑number changes, fusions or expression patterns that arose during a person’s life; distinguishing somatic from germline variants often requires comparison with a matched normal sample or specific bioinformatic filtering. Results reflect only the cells sampled and are limited by assay sensitivity, tumor or variant fraction, and the regions of the genome targeted by the test.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

11/09/2026 - 04:39 PM EST

SAN DIEGO, Nov. 9, 2026 /PRNewswire/ -- SOTERIA Precision Medicine Foundation, a non-profit 501(c)(3) organization, announced a collaboration with Tempus (NASDAQ: TEM) to deliver personalized, data-driven cancer treatment insights and advanced genomic sequencing to members of the U.S. active-duty and veteran military populations. The collaboration supports SOTERIA's Cancer Hunt^™ initiative, delivering precision oncology patient navigation with Tempus' comprehensive genomic profiling and AI-enabled diagnostic platform to help identify targeted therapies and clinical trial opportunities for active service members and veterans.

Members of the military communities are increasingly being diagnosed with cancer at younger ages and at advanced stages. SOTERIA addresses this critical care gap by providing patient-centric precision oncology navigation and facilitating CLIA-validated germline and somatic sequencing, ensuring that each patient's care is informed by comprehensive molecular data when possible.

"Our mission is to ensure that patients have access to the tools and technology that can inform the most effective treatment path for them," said Julia Civardi, Founder and CEO of SOTERIA. "Partnering with Tempus enables us to bring state-of-the-art genomic sequencing and AI analytics to our active service members and veterans, turning complex molecular data into clear, actionable treatment options for patients and care teams."

"Collaborating with SOTERIA allows us to put cutting-edge genomic insights directly into the hands of clinicians and their patients when every decision matters most," said Ezra Cohen, M.D., Chief Medical Officer of Oncology at Tempus. "We are proud to support SOTERIA's mission and help advance precision oncology for our nation's service members and veterans."

"As a member of the Special Operations community, I've seen the immense toll these cancers take," said CAPT Rob Newson, SEAL, USN (RET), PhD, Chief Community Officer at SOTERIA. "This initiative reflects the best of what's possible when technological innovation and service come together to support our military families."

Through this collaboration, Tempus and SOTERIA will continue to streamline molecular profiling and data integration across SOTERIA's patient cohort, advancing precision oncology research and optimizing care pathways for military community members diagnosed with cancer.

CANCER HUNT INQUIRIES